Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference24 articles.
1. Parham P. The Immune System 2nd Ed. New York: Garland Science; 2005. p. 227–76.
2. Zink T, Ross A, Lüers K, Cieslar C, Rudolph R, Holak TA. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry. 1994;33:8453–63.
3. Hill CP, Osslund TD, Eisenberg D. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc Natl Acad Sci U S A. 1993;90:5167–71.
4. Arakawa T, Prestrelski SJ, Narhi LO, Boone TC, Kenney WC. Cysteine 17 of recombinant human granulocyte-colony stimulating factor is partially solvent-exposed. J Protein Chem. 1993;12:525–31.
5. EMEA Comparability of biotechnological/biological products subject to changes in their manufacturing process. CPMP/ICH/5721/03, 13 (2006). Canada, H. GUIDANCE FOR SPONSORS: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). 2010/03/05. Health Canada - Publications, 17 (2010). FDA, U. Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Office of Communications US FDA UCM291134, 1-20 (2012). FDA, U. Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Office of Communications US FDA UCM291128, 1-25 (2012).
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献